Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects

Neurology

Volumn 63, Issue 12, 2004, Pages 2413-2415

  Haik S ^a   Brandel, J P ^a   Salomon, D ^a   Sazdovitch, V ^a   Delasnerie Laupretre N ^a   Laplanche, J L ^b   Faucheux, B A ^a   Soubrie C ^a   Boher, E ^c   Belorgey, C ^c   Hauw, J J ^a   Alperovitch ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

^c AFSSAPS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; MEPACRINE; PRION PROTEIN;

ARTICLE; CLINICAL ARTICLE; CREUTZFELDT JAKOB DISEASE; DRUG EFFICACY; DRUG WITHDRAWAL; FRANCE; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; LIVER DYSFUNCTION; NEUROPATHOLOGY; PRIORITY JOURNAL; RASH; RATING SCALE; SURVIVAL TIME;

EID: 19944375077     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000148596.15681.4D     Document Type: Article

References (10)

1. Doh-Ura K, Iwaki T, Caughey B. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie- associated prion protein accumulation. J Virol 2000;74:4894-4897.
2. Korth C, May BC, Cohen FE, Prusiner SB. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA 2001;98:9836-9841.
3. Josefson D. Drugs for malaria and psychosis may offer hope to people with CJD. Br Med J 2001;323:416.
4. World Health Organization. The revison of the variant Creutzfeldt-Jakob (vCJD) case definition. Report of a WHO consultation. Edinburgh, UK: WHO/CDS/CSR/EPH, 2001.
5. Brandel JP, Delasnerie-Lauprêtre N, Laplanche JL, Hauw JJ, Alpérovitch A. Diagnosis of Creutzfeldt-Jakob disease: effect of clinical criteria on incidence estimates. Neurology 2000;54:1095-1099.
6. Hauw JJ, Sazdovitch V, Laplanche JL, et al. Neuropathologic variants of sporadic Creutzfeldt-Jakob disease and codon 129 of PrP gene. Neurology 2000;54:1641-1646.
7. Barret A, Tagliavini F, Forloni G, et al. Evaluation of quinacrine treatment for prion diseases. J Virol 2003;77:8462-8469.
8. Collins SJ, Lewis V, Brazier M, Hill AF, Fletcher A, Masters CL. Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann Neurol 2002;52:503-506.
9. Doh-Ura K, Ishikawa K, Murakami-Kubo I, et al. Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol 2004;78:4999-5006.
10. Scoazec JY, Krolak-Salmon P, Casez O, et al. Quinacrine-induced cytolytic hepatitis in sporadic Creutzfeldt-Jakob disease. Ann Neurol 2003; 53:546-547.